Skip to main content

Table 2 Quality assessment of the trials according to the Cochrane Collaboration

From: Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials

Trials

A

B

C

D

E

F

Total score (n/12)

Blonde 2016 [9]

2

2

1

2

2

1

10

Forst 2014 [10]

2

2

1

1

2

1

9

Neal 2015 [11]

2

1

2

2

2

1

10

Gonzalez 2013 [12]

2

2

1

2

2

1

10

Inagaki 2013 [13]

2

2

1

1

2

1

9

Inagaki 2014

2

1

1

1

2

1

8

Stenlof 2013 [15]

2

1

2

2

2

1

10

Wilding 2013 [16]

2

1

2

2

2

1

10

Yale 2013 [17]

2

1

2

2

2

1

10

Rosenstock 2012 [18]

2

1

2

2

2

1

10

  1. A: sequence generation; B: concealment of allocation; C: Blinding of patients; D: Blinding of caregivers; E: Blinding of outcome assessors; F: Follow-up and intention-to treat analysis
Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us